Updates

Gaming Realms

October 2023

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

Gaming Realms has delivered a record H1. Revenues were up 36% to £11.5m, driven by continued growth in the core Content Licensing division (+37% to £8.8m), which launched five new Slingo games in H1 23 (70 in total at end of June), and has had launches with an additional 25 partners (162 in total). North America was 45% of total sales with more market launches planned (including Greece and South Africa) along with further growth expected from the markets that launched in FY22 (Ontario, Quebec, Connecticut, Spain, Belgium and Denmark). Adjusted H1 23 EBITDA was £4.8m, +37%, with EBITDA margin up by 30bps to 41.2%. Net cash was £4.5m, up £1.6m since December. Momentum has continued into H2 with licensing growth of 20% across the fir ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Alpha Group

Brave Bison

Gaming Realms (May 2024)

Gaming Realms (February 2022)

Gaming Realms (October 2021)

Gaming Realms (February 2021)

Gaming Realms - Licencing revenue +80% in April and May (July 2020)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X